In Vitro and In Vivo Drug-Response Profiling Using Patient-Derived High-Grade Glioma.

ABSTRACT:

Background

Genomic profiling cannot solely predict the complexity of how tumor cells behave in their in vivo microenvironment and their susceptibility to therapies. The aim of the study was to establish a functional drug prediction model utilizing patient-derived GBM tumor samples for in vitro testing of drug efficacy followed by in vivo validation to overcome the disadvantages of a strict pharmacogenomics approach.

Methods

High-throughput in vitro pharmacologic testing of patient-derived GBM tumors cultured as 3D organoids offered a cost-effective, clinically and phenotypically relevant model, inclusive of tumor plasticity and stroma. RNAseq analysis supplemented this 128-compound screening to predict more efficacious and patient-specific drug combinations with additional t

SUBMITTER: Rajan RG 

PROVIDER: S-EPMC10339991 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature